129 related articles for article (PubMed ID: 33098080)
1. Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.
Nakada H; Folkers KM; Takashima K
Ther Innov Regul Sci; 2021 Mar; 55(2):401-407. PubMed ID: 33098080
[TBL] [Abstract][Full Text] [Related]
2. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
Bunnik EM; Aarts N; van de Vathorst S
Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
[TBL] [Abstract][Full Text] [Related]
3. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
Bunnik EM; Aarts N
BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
[TBL] [Abstract][Full Text] [Related]
4. Where Can Patients Obtain Information on the Preapproval Access Pathway to Investigational Treatment in Japan? A Survey of Patient Advocacy Organizations' Websites.
Nakada H; Takashima K
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):978-983. PubMed ID: 31592580
[TBL] [Abstract][Full Text] [Related]
5. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
[TBL] [Abstract][Full Text] [Related]
6. Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.
Pinxten W; Nys H; Dierickx K
J Med Ethics; 2010 Dec; 36(12):791-4. PubMed ID: 20852303
[TBL] [Abstract][Full Text] [Related]
7. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
Chapman CR; Eckman J; Bateman-House AS
Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
[TBL] [Abstract][Full Text] [Related]
8. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications.
Bunnik EM; Aarts N; van de Vathorst S
J Pharm Policy Pract; 2017; 10():10. PubMed ID: 28239479
[TBL] [Abstract][Full Text] [Related]
9. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
Fountzilas E; Said R; Tsimberidou AM
Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
[TBL] [Abstract][Full Text] [Related]
10. Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.
Klopfenstein M; Van Campen LE; Garnett T
Ther Innov Regul Sci; 2015 May; 49(3):352-358. PubMed ID: 29473010
[TBL] [Abstract][Full Text] [Related]
11. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
12. Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework.
Mehrotra N; Manchikanti P
Med Law Rev; 2024 Feb; 32(1):20-41. PubMed ID: 37616571
[TBL] [Abstract][Full Text] [Related]
13. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
Smith C; Stout J; Adjei AA; Buckner J; Wentworth M; Tilburt J; Master Z
J Natl Cancer Inst; 2021 Jun; 113(6):735-741. PubMed ID: 32882030
[TBL] [Abstract][Full Text] [Related]
14. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
Hordijk M; Vermeulen SF; Bunnik EM
Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
[TBL] [Abstract][Full Text] [Related]
15. Ensuring Justice in Access to Investigational Neurological Drugs.
Kearns L; Bateman-House A; Caplan A
Semin Neurol; 2018 Oct; 38(5):583-588. PubMed ID: 30321898
[TBL] [Abstract][Full Text] [Related]
16. Conflicts of interest in research involving human beings.
Greco D; Diniz NM
J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
[TBL] [Abstract][Full Text] [Related]
17. Genomics and High-Consequence Infectious Diseases: A Scoping Review of Emerging Science and Potential Ethical Issues.
Boyce AM; Garibaldi BT
Health Secur; 2019; 17(1):62-68. PubMed ID: 30724614
[TBL] [Abstract][Full Text] [Related]
18. Ethical issues on the "synthetic" phosphoethanolamine clinical trial.
Paumgartten FJR
Rev Assoc Med Bras (1992); 2017 May; 63(5):388-392. PubMed ID: 28724033
[TBL] [Abstract][Full Text] [Related]
19. The patient's safety and access to experimental drugs after the termination of clinical trials: regulations and trends.
da Silva RE; Amato AA; Sousa TDR; de Carvalho MR; Novaes MRCG
Eur J Clin Pharmacol; 2018 Aug; 74(8):1001-1010. PubMed ID: 29754216
[TBL] [Abstract][Full Text] [Related]
20. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
